Pharma Equity Group (“PEG” or “the Company”) has recently refined the Company’s execution strategy, prioritizing resources toward three key candidates, RNX-051, RNX-011, and RNX-041, where the Company identifies the shortest path to market and strong...

Pharma Equity Group (“PEG” or “the Company”) published its Year-End report for 2024 on the 20th of March 2025.

Pharma Equity Group (“PEG” or “the Company”) announced on Friday, December the 13th, the board of directors’ decision on a new execution strategy and prioritization of clinical areas regarding the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex...

Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding through a directed share issue, with a significant portion allocated to debt reduction. This strengthens the Company’s financial position, providing increased...

Pharma Equity Group (“PEG” or “the Company”) published its Q3 report for 2024 on the 15th of November 2024.

Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Company’s subsidiary Reponex Pharmaceuticals A/S (“Reponex”) has obtained patent protection in Japan for the treatment of colorectal cancer with RNX-051, ...